Concourse Financial Group Securities, Inc. Vectiv Bio Holding Ag Transaction History

Concourse Financial Group Securities, Inc.

  • $1.56 Billion
  • Q2 2024

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 10, 2023
BUY
$8.29 - $16.97 $0 - $0
0 New
0 $0
Q1 2023

May 15, 2023
BUY
$7.34 - $9.15 $0 - $0
0 New
0 $0
Q4 2022

Jan 30, 2023
BUY
$7.79 - $8.98 $0 - $0
0 New
0 $0
Q3 2022

Nov 15, 2022
BUY
$4.7 - $6.07 $0 - $0
0 New
0 $0
Q2 2022

Aug 09, 2022
BUY
$4.2 - $6.55 $0 - $0
0 New
0 $0
Q1 2022

May 09, 2022
BUY
$4.6 - $5.8 $0 - $0
0 New
0 $0
Q4 2021

Feb 07, 2022
BUY
$2.83 - $7.26 $0 - $0
0 New
0 $0
Q3 2021

Nov 09, 2021
BUY
$6.7 - $11.54 $0 - $0
0 New
0 $0
Q2 2021

Aug 13, 2021
BUY
$11.66 - $24.23 $0 - $0
0 New
0 $0

Others Institutions Holding VECT

# of Institutions
1
Shares Held
510K
Call Options Held
0
Put Options Held
0
View Full List

About VectivBio Holding AG

VECT Quotes by TradingView
  • Ticker VECT
  • Exchange NASDAQ
  • Description
  • VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with sho...
More about VECT
Track This Portfolio

Track Concourse Financial Group Securities, Inc. Portfolio

Follow Concourse Financial Group Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email